User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Primary tabs

Bento, L Boumendil, A Finel, H Le Gouill, S Amorim, S Poire, Xavier [UCL] The Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively. BEAM, Z-BEAM and R-BEAM groups were well balanced for age, time from diagnosis to ASCT and disease status at ASCT. The cumulative incidences of relapse (IR) at 2 years were 34, 34 and 32% for Z-BEAM, R-BEAM and BEAM, respectively. By multivariate analysis, there were no significant differences with Z-BEAM or R-BEAM compared with BEAM for IR, non-relapse mortality, event-free survival or overall survival. With the caveat that the limitations of registry analyses have to be taken into account, this study does not support adding radioimmunotherapy or R to BEAM in ASCT for relapsed FL. However, we cannot rule out the existence a particular subset of patients who could benefit from Z-BEAM conditioning that cannot be identified in our series, and this should be tested in a randomized trial.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2017
Language Anglais
Journal information "Bone Marrow Transplantation" - Vol. 52, no.8, p. 1120-1125 (2017)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 0268-3369
e-issn 1476-5365
Publication status Publié
Affiliations UCL - SSS/IREC/SLUC - Pôle St.-Luc
UCL - (SLuc) Service d'hématologie
Links
  1. Montoto S., Corradini P., Dreyling M., Ghielmini M., Kimby E., Lopez-Guillermo A., Mackinnon S., Marcus R. E., Salles G., Schouten H. C., Sureda A., Dreger P., Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party, 10.3324/haematol.2013.084723
  2. El-Najjar I., Boumendil A., Luan J. J., Bouabdallah R., Thomson K., Mohty M., Colombat P., Biron P., Tilly H., Pfreundschuh M., Cordonnier C., Sureda A., Cahn J. Y., Vernant J. P., Gribben J., Cook G., Haynes A. P., Ferrant A., Finel H., Montoto S., Dreger P., The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party†, 10.1093/annonc/mdu440
  3. Montoto S, , Canals C, Rohatiner A Z S, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister T A, Goldstone A H, Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study, 10.1038/sj.leu.2404850
  4. Rohatiner Ama Z.S., Nadler Lee, Davies Andrew J., Apostolidis John, Neuberg Donna, Matthews Janet, Gribben John G., Mauch Peter M., Lister T. Andrew, Freedman Arnold S., Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up, 10.1200/jco.2006.09.8327
  5. Pettengell Ruth, Schmitz Norbert, Gisselbrecht Christian, Smith Graeme, Patton William N., Metzner Bernd, Caballero Dolores, Tilly Herve, Walewski Jan A., Bence-Bruckler Isabelle, To Bik, Geisler Christian H., Schots Rik, Kimby Eva, Taverna Christian J., Kozák Tomáš, Dreger Peter, Uddin Ruzena, Ruiz de Elvira Carmen, Goldstone Anthony H., Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, 10.1200/jco.2012.47.1862
  6. Vose Julie M., Carter Shelly, Burns Linda J., Ayala Ernesto, Press Oliver W., Moskowitz Craig H., Stadtmauer Edward A., Mineshi Shin, Ambinder Richard, Fenske Timothy, Horowitz Mary, Fisher Richard, Tomblyn Marcie, Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial, 10.1200/jco.2012.45.9453
  7. Gopal A. K., High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis, 10.1182/blood-2003-02-0622
  8. Winter Jane N., Inwards David J., Spies Stewart, Wiseman Gregory, Patton David, Erwin William, Rademaker Alfred W., Weitner Bing Bing, Williams Stephanie F., Tallman Martin S., Micallef Ivana, Mehta Jayesh, Singhal Seema, Evens Andrew M., Zimmer Michael, Molina Arturo, White Christine A., Gordon Leo I., Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma, 10.1200/jco.2008.19.2245
  9. Dreyling M., Trümper L., von Schilling C., Rummel M., Holtkamp U., Waldmann A., Wehmeyer J., Freund M., Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma—role of radioimmunotherapy, 10.1007/s00277-006-0207-0
  10. Witzig Thomas E., Fishkin Paul, Gordon Leo I., Gregory Stephanie A., Jacobs Samuel, Macklis Roger, Mclaughlin Peter, Press Oliver, Zelenetz Andrew D., Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report, 10.3109/10428194.2011.570396
  11. Decaudin Didier, Mounier Nicolas, Tilly Hervé, Ribrag Vincent, Ghesquières Hervé, Bouabdallah Krimo, Morschhauser Franck, Coiffier Bertrand, Le Gouill Steven, Bologna Serge, Delarue Richard, Huynh Anne, Bosly André, Brière Josette, Gisselbrecht Christian, 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study, 10.1016/j.clml.2011.03.007
  12. Gisselbrecht C., Vose J., Nademanee A., Gianni A. M., Nagler A., Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response, 10.1634/theoncologist.2009-s2-41
  13. Dreyling M., Ghielmini M., Rule S., Salles G., Vitolo U., Ladetto M., Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, 10.1093/annonc/mdw400
  14. Morschhauser Franck, Kraeber-Bodéré Françoise, Wegener William A., Harousseau Jean-Luc, Petillon Marie-Odile, Huglo Damien, Trümper Lorenz H., Meller Johannes, Pfreundschuh Michael, Kirsch Carl-Martin, Naumann Ralph, Kropp Joachim, Horne Heather, Teoh Nick, Le Gouill Steven, Bodet-Milin Caroline, Chatal Jean-Francois, Goldenberg David M., High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma, 10.1200/jco.2009.27.7863
  15. Krishnan Amrita, Nademanee Auayporn, Fung Henry C., Raubitschek Andrew A., Molina Arturo, Yamauchi Dave, Rodriguez Roberto, Spielberger Ricardo T., Falk Peter, Palmer Joycelynne M., Forman Stephen J., Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma, 10.1200/jco.2007.11.9248
  16. Nademanee A., A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma, 10.1182/blood-2005-03-1310
  17. Shimoni Avichai, Zwas S. Tzila, Oksman Yakov, Hardan Izhar, Shem-Tov Noga, Yerushalmi Ronit, Avigdor Abraham, Ben-Bassat Isaac, Nagler Arnon, Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma, 10.1016/j.exphem.2007.01.043
  18. Shimoni Avichai, Avivi Irit, Rowe Jacob M., Yeshurun Moshe, Levi Itai, Or Reuven, Patachenko Paulina, Avigdor Abraham, Zwas Tzila, Nagler Arnon, A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma, 10.1002/cncr.27418
  19. Ghielmini M., Vitolo U., Kimby E., Montoto S., Walewski J., Pfreundschuh M., Federico M., Hoskin P., McNamara C., Caligaris-Cappio F., Stilgenbauer S., Marcus R., Trneny M., Dreger P., Montserrat E., Dreyling M., Agostinelli C., Arcaini L., Caligaris-Cappio F., Campo E., Coiffier B., Corradini P., D'Amore F., Dreger P., Dreyling M., Federico M., Gallamini A., Gaulard P., Geisler C. H., Ghielmini M., Gisselbrecht C., da Silva M. G., Gribben J., Hermine O., Hoskin P., Iannitto E., Kim W. S., Kimby E., Kluin-Nelemans H. C., Koch P., Ladetto M., Le Gouill S., Lopez-Guillermo A., Marcus R., McNamara C., Montalban C., Montoto S., Montserrat E., Pfreundschuh M., Raderer M., Rodriguez J., Salles G., Bernard C., Schmitz N., Shpilberg O., Stilgenbauer S., Thieblemont C., Tilly H., Tournilhac O., Trumper L., Vitolo U., Walewski J., Wotherspoon A., Zucca E., , ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), 10.1093/annonc/mds517
  20. Salles Gilles, Seymour John Francis, Offner Fritz, López-Guillermo Armando, Belada David, Xerri Luc, Feugier Pierre, Bouabdallah Réda, Catalano John Vincent, Brice Pauline, Caballero Dolores, Haioun Corinne, Pedersen Lars Moller, Delmer Alain, Simpson David, Leppa Sirpa, Soubeyran Pierre, Hagenbeek Anton, Casasnovas Olivier, Intragumtornchai Tanin, Fermé Christophe, da Silva Maria Gomes, Sebban Catherine, Lister Andrew, Estell Jane A, Milone Gustavo, Sonet Anne, Mendila Myriam, Coiffier Bertrand, Tilly Hervé, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, 10.1016/s0140-6736(10)62175-7
  21. Czuczman Myron S., Emmanouilides Christos, Darif Mohamed, Witzig Thomas E., Gordon Leo I., Revell Stephen, Vo Katie, Molina Arturo, Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy, 10.1200/jco.2006.09.2882
  22. Bennett J. M., Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, 10.1182/blood-2004-12-4690
  23. Devizzi Liliana, Guidetti Anna, Tarella Corrado, Magni Michele, Matteucci Paola, Seregni Ettore, Chiesa Carlo, Bombardieri Emilio, Di Nicola Massimo, Carlo-Stella Carmelo, Gianni Alessandro M., High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation, 10.1200/jco.2008.16.8294
Bibliographic reference Bento, L ; Boumendil, A ; Finel, H ; Le Gouill, S ; Amorim, S ; et. al. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.. In: Bone Marrow Transplantation, Vol. 52, no.8, p. 1120-1125 (2017)
Permanent URL http://hdl.handle.net/2078.1/203648